Breaking News

Cellipont Bioservices, Adva Biotechnology Partner to Optimize Cell Therapy Mfg.

To leverage ADVA X3 Platform designed to simplify and accelerate the manufacturing of CAR-T therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cellipont Bioservices, a cell therapy CDMO, and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated manufacturing platform for advanced cell therapies, partnered to leverage Adva Biotechnology’s ADVA X3 platform in North America. The ADVA X3 is an advanced, fully automated platform for manufacturing cell therapies, that aims to streamline processes and reduce costs.     The ADVA X3 system is designed to simplify and accelerate the manufacturin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters